Latest News: Technology |  Celebrity |  Movies |  Apple |  Cars |  Business |  Sports |  TV Shows |  Geek

Trending

Filed under: News

 

FDA Panel Once Again Rejects New Indication For J&J Drug

FDA Panel Once Again Rejects New Indication For J&J Drug
Photo Credit: Forbes
 
 

The FDA’s Cardiovascular and Renal Drugs Advisory Committee once again turned down the supplemental new drug application for an acute coronary syndrome indication for Johnson & Johnson’s Xarelto (rivaroxaban). The nearly unanimous vote (10-0, with 1 abstention) was in line with a highly negative review from FDA staff members.

Although originally the subject of high praise when it first came out, the pivotal title="ATLAS ACS 2-TIMI 51: Rivaroxaban Beneficial in Low-Risk ACS Population">ATLAS ACS 2-TIMI 51 trial has been bedeviled by criticism since the FDA drew attention to the unusually large amount of missing trial data. Previous discussions of the trial at the FDA brought the word “missingness” into common usage in the medical community. Although J&J made efforts to supply some of the missing data this time around, ultimately the panel members agreed with the most recent assessment from the FDA reviewers that the large amount of still-missing data made it impossible to reach firm conclusions about the relative safety and efficacy of the drug in the setting of ACS.

Panel member Linda Fried, from the University of Pittsburgh, gave voice to a view adopted by many of the committee members. ATLAS, she said, was probably “an overall positive study” but, because of the large amount of missing data and the absence of a confirmatory study, was “not robust enough” to support the ACS indication. Speaking on behalf of the sponsor, cardiologists C. Michael Gibson and Marvin Konstam tried to persuade the panel to accept their multiple positive analyses of the trial. But panel members, including outspoken critics like Steve Nissen and Sanjay Kaul, left little doubt throughout the day’s meeting that they were unlikely to vote in favor of the new indication.

“We appreciate the thoroughness of the committee’s review and continue to believe rivaroxaban, in addition to the current standard of care, may help provide patients with ACS additional protection against life-threatening cardiovascular events such as death, heart attack and stroke. We will work with the FDA to address questions raised today,” said J&J’s Paul Burton, in a statement.

Source: Forbes

iPad Air Giveaway. Win a free iPad Air.

You Might Also Like

Updates

Shopping Deals

 
 
 

<a href="/latest_stories/all/all/31" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

 

Comments

blog comments powered by Disqus

Latest stories

Kari Byron, Tory Belleci and Grant Imahara Exit MythBusters
 
 
Microsoft set to unveil Windows 9 on September 30th
Microsoft set to unveil Windows 9 on September 30th
While Threshold is likely to be named Windows 9, it’s unlikely that Microsoft will name its upcoming Windows release at its press event.
 
 
Tara Reid Wears Revealing Dress at Sharknado 2 Screening
Tara Reid Wears Revealing Dress at Sharknado 2 Screening
Sharknado 2 hit the big screen yesterday in LA. Tara Reid used the occasion for a dramatic red carpet appearance. How does this dress stay on her boobs?
 
 
Mariah Carey Feels Sorry About her Marital Issues
Mariah Carey Feels Sorry About her Marital Issues
The pop diva, Mariah Carey feels sorry about her marital issues. Her problems with her husband may offer trouble in the future for the rich and famous songstress.
 
 
 

About the Geek Mind

The “geek mind” is concerned with more than just the latest iPhone rumors, or which company will win the gaming console wars. I4U is concerned with more than just the latest photo shoot or other celebrity gossip.

The “geek mind” is concerned with life, in all its different forms and facets. The geek mind wants to know about societal and financial issues, both abroad and at home. If a Fortune 500 decides to raise their minimum wage, or any high priority news, the geek mind wants to know. The geek mind wants to know the top teams in the National Football League, or who’s likely to win the NBA Finals this coming year. The geek mind wants to know who the hottest new models are, or whether the newest blockbuster movie is worth seeing. The geek mind wants to know. The geek mind wants—needs—knowledge.

Read more about The Geek Mind.